{(S)-5-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-5-[4-(6-methoxyquinolin-8-ylamino)pentylcarbamoyl]pentyl}carbamic acid tert-butyl ester | 918797-41-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: {(S)-5-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-5-[4-(6-methoxyquinolin-8-ylamino)pentylcarbamoyl]pentyl}carbamic acid tert-butyl ester
• 英文别名: Cbz-Leu-Lys(Boc)-Primaquine；4'-N-[benzyloxycarbonyl-L-leucyl-(N-^ε-tert-butoxycarbonyl-L-lysyl)]primaquine；tert-butyl N-[(5S)-6-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]-5-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-6-oxohexyl]carbamate
• CAS: 918797-41-8
• 化学式: C₄₀H₅₈N₆O₇
• 分子量: 734.937
• InChiKey: YJNFCJNJFFKAPQ-CJIPUWSSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  53
• 可旋转键数：
  23
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  169
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  {(S)-5-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-5-[4-(6-methoxyquinolin-8-ylamino)pentylcarbamoyl]pentyl}carbamic acid tert-butyl ester 在 palladium on activated charcoal N-甲基吗啉 、 氢气 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl N-[(5S)-5-[[(2S)-2-[[4-[4-[[(2S,3S)-1-[[(3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]phenoxy]benzoyl]amino]-4-methylpentanoyl]amino]-6-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]-6-oxohexyl]carbamate
  参考文献：
  名称：

  High Antiplasmodial Activity of Novel Plasmepsins I and II Inhibitors

  摘要：

  The aim of this study was to develop new antiplasmodial compounds acting through distinct mechanisms during both the liver and the blood stages of the parasite life cycle. Compounds were designed on the basis of the "double-drug" approach: primaquine, which has been linked to statine-based inhibitors of plasmepsins (PLMs), the plasmodial aspartic proteases involved in degradation of hemeoglobin. The compounds were tested in vitro for anti-PLM I/PLM II activities and against chloroquine-sensitive (D10) and chloroquine-resistant (W2) strains of P. falciparum. An antiplasmodial activity (IC50) as low as 0.1 mu M was obtained, an excellent improvement in comparison with inhibitors previously reported (IC50 = 2 - 20 mu M). The killing activity was equally directed against both P. falciparum strains and was correlated to lipophilicity (calculated as ALogP), for all compounds but one (9). All compounds inhibited PLM I and PLM II in the nanomolar range (K-i = 1 - 700 nM). The most promising compounds (2, 6, 10) were not cytotoxic against human fibroblasts at 100 mu M and were highly selective for PLMs vs human cathepsin D.

  DOI：

  10.1021/jm061033d
• 作为产物：
  描述：

  N-苄氧羰基-L-亮氨酸 、 tert-butyl [(5S)-5-amino-6-({4-[(6-methoxyquinolin-8-yl)amino]pentyl}amino)-6-oxohexyl]carbamate 在 N-甲基吗啉 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以69%的产率得到{(S)-5-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-5-[4-(6-methoxyquinolin-8-ylamino)pentylcarbamoyl]pentyl}carbamic acid tert-butyl ester
  参考文献：
  名称：

  High Antiplasmodial Activity of Novel Plasmepsins I and II Inhibitors

  摘要：

  The aim of this study was to develop new antiplasmodial compounds acting through distinct mechanisms during both the liver and the blood stages of the parasite life cycle. Compounds were designed on the basis of the "double-drug" approach: primaquine, which has been linked to statine-based inhibitors of plasmepsins (PLMs), the plasmodial aspartic proteases involved in degradation of hemeoglobin. The compounds were tested in vitro for anti-PLM I/PLM II activities and against chloroquine-sensitive (D10) and chloroquine-resistant (W2) strains of P. falciparum. An antiplasmodial activity (IC50) as low as 0.1 mu M was obtained, an excellent improvement in comparison with inhibitors previously reported (IC50 = 2 - 20 mu M). The killing activity was equally directed against both P. falciparum strains and was correlated to lipophilicity (calculated as ALogP), for all compounds but one (9). All compounds inhibited PLM I and PLM II in the nanomolar range (K-i = 1 - 700 nM). The most promising compounds (2, 6, 10) were not cytotoxic against human fibroblasts at 100 mu M and were highly selective for PLMs vs human cathepsin D.

  DOI：

  10.1021/jm061033d

文献信息

• Plasmepsin II inhibition and antiplasmodial activity of Primaquine–Statine `double-drugs'
  作者：Sergio Romeo、Mario Dell'Agli、Silvia Parapini、Luca Rizzi、Germana Galli、Monica Mondani、Anna Sparatore、Donatella Taramelli、Enrica Bosisio

  DOI：10.1016/j.bmcl.2004.03.030

  日期：2004.6

  Statine-based inhibitors of Plasmepsin II (PLMII) coupled with Primaquine have been designed using the 'double-drug' approach. The IC50 values for PLMII inhibition ranged from 0.59 to 400 nM and the best IC50 value for inhibition of Plasmodium falciparum growth in vitro was 0.4 muM, which represent a remarkable improvement compared to other statine-based PLMII inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.
• High Antiplasmodial Activity of Novel Plasmepsins I and II Inhibitors
  作者：Mario Dell'Agli、Silvia Parapini、Germana Galli、Nadia Vaiana、Donatella Taramelli、Anna Sparatore、Peng Liu、Ben M. Dunn、Enrica Bosisio、Sergio Romeo

  DOI：10.1021/jm061033d

  日期：2006.12.1

  The aim of this study was to develop new antiplasmodial compounds acting through distinct mechanisms during both the liver and the blood stages of the parasite life cycle. Compounds were designed on the basis of the "double-drug" approach: primaquine, which has been linked to statine-based inhibitors of plasmepsins (PLMs), the plasmodial aspartic proteases involved in degradation of hemeoglobin. The compounds were tested in vitro for anti-PLM I/PLM II activities and against chloroquine-sensitive (D10) and chloroquine-resistant (W2) strains of P. falciparum. An antiplasmodial activity (IC50) as low as 0.1 mu M was obtained, an excellent improvement in comparison with inhibitors previously reported (IC50 = 2 - 20 mu M). The killing activity was equally directed against both P. falciparum strains and was correlated to lipophilicity (calculated as ALogP), for all compounds but one (9). All compounds inhibited PLM I and PLM II in the nanomolar range (K-i = 1 - 700 nM). The most promising compounds (2, 6, 10) were not cytotoxic against human fibroblasts at 100 mu M and were highly selective for PLMs vs human cathepsin D.